Magle Chemoswed Holding AB (publ) Stock Nasdaq Stockholm
Equities
SE0014401014
Pharmaceuticals
Sales 2024 * | 189M 17.23M | Sales 2025 * | 206M 18.79M | Capitalization | 326M 29.68M |
---|---|---|---|---|---|
Net income 2024 * | 24M 2.18M | Net income 2025 * | 30M 2.73M | EV / Sales 2024 * | 1.95 x |
Net Debt 2024 * | 42.5M 3.87M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.58 x |
P/E ratio 2024 * |
13.7
x | P/E ratio 2025 * |
30.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.39% |
Managers | Title | Age | Since |
---|---|---|---|
Justin Pierce
CEO | Chief Executive Officer | 51 | 14-12-31 |
Petra Sjölin
DFI | Director of Finance/CFO | - | 20-06-30 |
Chief Operating Officer | 48 | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 15-12-31 | |
Director/Board Member | 79 | 15-12-31 | |
Director/Board Member | 44 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+27.97% | 672B | |
+23.58% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.96% | 211B | |
-0.41% | 203B | |
-10.02% | 194B | |
-11.81% | 144B |